USPTO to Re-examine Two Patents in Affymetrix, Illumina Litigation | GenomeWeb
NEW YORK (GenomeWeb News) – Illumina said today that the US Patent and Trademark Office has ordered a re-examination of two patents at the heart of ongoing intellectual property litigation between the firm and Affymetrix.
 
The two patents being re-examined are No. 6,355,432, entitled “Products for detecting nucleic acids,” and No. 6,646,243, entitled “Nucleic acid reading and analysis system.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.